ScandiBio Therapeutics AB Initiates Phase 3 Clinical Trial for Alzheimer's Disease
Alzheimer's disease is the most common cause of dementia, leading to memory loss and cognitive impairments that interfere with daily life.
A growing body of evidence suggests that impaired brain energy metabolism and mitochondrial dysfunction contribute to cognitive decline in AD.
The aim is to improve mitochondrial dysfunction by treating patients with the proprietary Combined Metabolic Activator (CMA2) drug.
ScandiBio Therapeutics AB announced the initiation of a multicentre, phase 3 human clinical trial evaluating the efficacy and safety of CMA in patients with Alzheimer's disease.
- The trial is taking place across nine clinical centres in Turkey.
- It targets patients with mild, moderate, and severe symptoms.
Author's summary: ScandiBio initiates phase 3 trial for Alzheimer's disease treatment.
More News
- Cerealto takes majority stake in US manufacturer Fresca Foods | FoodBev Media
- Cerealto marks US entry with stake in co-manufacturing peer Fresca Foods
- Numbers on remand a ‘key factor’ driving prison capacity crisis – The Justice Gap
- Policy Brief: Internet Shutdowns - Internet Society
- First Person: Kerem Hasan on the transformative experience of conducting Jake Heggie's 'Dead Man Walking'
- Cob launches corn-free ‘Popcorn’ brand backed by Novak Djokovic | FoodBev Media
- 'Hero' train crew member who protected passengers during mass stabbing named
- John Lewis unveils tear-jerking Christmas advert set to iconic 90s club classic
- SA ‘success story’ GBS sector adds over 8K jobs
- FoodBev Media reveals Global Water Drinks Awards 2025 shortlist | FoodBev Media